Table 1. Baseline patients characteristics (n=30).
| n | % | |
|---|---|---|
| Gender: male/female | 16/14 | 53/47 |
| Median age (range, in years) | 59 (31–80) | |
| Primary melanoma | ||
| SSM | 17 | 57 |
| Nodular | 4 | 13 |
| Uveal | 3 | 10 |
| Unknown primary | 4 | 13 |
| Others | 2 | 7 |
| AJCC stage IV | ||
| M1a | 1 | 3 |
| M1b | 2 | 7 |
| M1c | 27 | 90 |
| >2 Metastatic sites | 22 | 73 |
| Lung metastases | 18 | 60 |
| Liver metastases | 19 | 63 |
| Brain metastases | 10 | 33 |
| LDH>N | 14 | 47 |
| Previous chemotherapy | 28 | 93 |
| ⩾2 Lines of chemotherapy | 22 | 73 |
| Performance Status (WHO) | ||
| 0–1 | 24 | 80 |
| 2–3 | 6 | 20 |
| Median time from first metastasis (range, in months) | 15 (1–59) | |
Abbreviations: AJCC=American Joint Committee on Cancer; LDH=lactate dehydrogenase; SSM=spreading superficial melanoma.